摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Boc-norstatine | 222640-10-0

中文名称
——
中文别名
——
英文名称
N-Boc-norstatine
英文别名
(3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-5-methylhexanoic acid;3(S)-t-butoxycarbonylamino-2-hydroxy-5-methylhexanoic acid;(2RS,3S)-3-tert-butyloxycarbonylamino-2-hydroxy-5-methylhexanoic acid;(3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
N-Boc-norstatine化学式
CAS
222640-10-0
化学式
C12H23NO5
mdl
——
分子量
261.318
InChiKey
DJZCWTDKDFJARG-IENPIDJESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    18
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    95.9
  • 氢给体数:
    3
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid
    摘要:
    The 2S,3S and 2R,3S diastereoisomers of the hydroxy amino acid 3-amino-2-hydroxy-5-methylhexanoic acid (AHMHA) were synthesized and substituted for the leucyl residues of Leu-Leu-Val-Phe-OCH3 to yield the following analogues: AHMHA-Leu-Val-Phe-OCH3, AHMHA-Val-Phe-OCH3, and Leu-AHMHA-Val-Phe-OCH3. These analogues were tested in vitro for their ability to inhibit human amniotic renin. All of the analogues were found to inhibit renin to some extent with inhibitory constants in the range of 10(-3) to 10(-4) M. The analogues AHMHA-Leu-Val-Phe-OCH3 and AHMHA-Val-Phe-OCH3 exhibited competitive inhibition when the 2S,3S isomer of AHMHA was employed and noncompetitive kinetics when the 2R,3S isomer of AHMHA was used. For the Leu-AHMHA-Val-Phe-OCH3 analogues, competitive kinetics were observed regardless of the isomer of AHMHA employed. These latter analogues also proved to be the most active in the above series.
    DOI:
    10.1021/jm00347a024
  • 作为产物:
    描述:
    N-phthalimide-L-leucinyl chloride 在 Pd-BaSO4 盐酸氢气三乙胺 、 zinc(II) iodide 作用下, 以 1,4-二氧六环二氯甲烷 、 xylene 为溶剂, 反应 67.5h, 生成 N-Boc-norstatine
    参考文献:
    名称:
    Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid
    摘要:
    The 2S,3S and 2R,3S diastereoisomers of the hydroxy amino acid 3-amino-2-hydroxy-5-methylhexanoic acid (AHMHA) were synthesized and substituted for the leucyl residues of Leu-Leu-Val-Phe-OCH3 to yield the following analogues: AHMHA-Leu-Val-Phe-OCH3, AHMHA-Val-Phe-OCH3, and Leu-AHMHA-Val-Phe-OCH3. These analogues were tested in vitro for their ability to inhibit human amniotic renin. All of the analogues were found to inhibit renin to some extent with inhibitory constants in the range of 10(-3) to 10(-4) M. The analogues AHMHA-Leu-Val-Phe-OCH3 and AHMHA-Val-Phe-OCH3 exhibited competitive inhibition when the 2S,3S isomer of AHMHA was employed and noncompetitive kinetics when the 2R,3S isomer of AHMHA was used. For the Leu-AHMHA-Val-Phe-OCH3 analogues, competitive kinetics were observed regardless of the isomer of AHMHA employed. These latter analogues also proved to be the most active in the above series.
    DOI:
    10.1021/jm00347a024
点击查看最新优质反应信息

文献信息

  • [EN] ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF<br/>[FR] DERIVE D'ALPHA-CETOAMIDE, SON PROCEDE DE PRODUCTION ET D'UTILISATION
    申请人:SENJU PHARMA CO
    公开号:WO2005056519A1
    公开(公告)日:2005-06-23
    The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity.
    本发明提供了一种化合物,其化学式表示为(I):(插入化学式)(其中R1是由低烷基取代的低烷氧基或杂环基,或者是杂环基;R2是可选择地由苯基取代的低烷基;R3是可选择地由卤素、低烷氧基或苯基取代的低烷基,或者是融合的多环碳氢基),该化合物在口服后被很好地吸收,表现出良好的血液水平持久性,并具有强大的钙蛋白酶抑制活性。
  • COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER
    申请人:OSAKA CITY UNIVERSITY
    公开号:US20190314320A1
    公开(公告)日:2019-10-17
    The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I): wherein R 1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): R 4 O—R 5  m (IIa) wherein R 4 is lower alkyl, R 5 is lower alkylene, and m is an integer of 1 to 6; R 2 is lower alkyl optionally substituted with phenyl; and R 3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.
    本发明提供了一种治疗和/或预防外周神经障碍的方法,通过促进外周神经再生。具体地,本发明提供了一种用于治疗和/或预防外周神经障碍的组合物,包括由通式(I)表示的化合物: 其中R1为与低烷氧基取代的低烷基,与杂环基取代的低烷基,杂环基,或由式(IIa)表示的基团: R4O—R5m(IIa) 其中R4为低烷基,R5为低烷基烯,m为1至6的整数; R2为可选择地取代苯基的低烷基;和 R3为可选择地取代卤素,低烷氧基,或苯基的低烷基;缩合多环碳氢化合物;或氢。
  • Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
    申请人:——
    公开号:US20040204368A1
    公开(公告)日:2004-10-14
    An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1 wherein all symbols have the same meaning as described in the specification. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation system(s) disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.
    公式(I)的一种噁二唑衍生物及其非毒性盐, 其中所有符号的含义与规范中描述的相同。公式(I)的化合物具有对半胱氨酸蛋白酶的抑制活性,因此它可用作预防和/或治疗炎症性疾病、由细胞凋亡引起的疾病、由免疫反应紊乱引起的疾病、自身免疫疾病、由构成生物体的蛋白质分解引起的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症(AIDS)和AIDS相关综合症(ARC)、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌亢进等方面的药剂。
  • Histidine derivatives
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:US04656269A1
    公开(公告)日:1987-04-07
    Novel amino acid derivatives useful as a therapeutic agent are disclosed. These amino acid derivatives and the pharmaceutically acceptable salts thereof have a human renin inhibitory effect when administered orally and are useful for treatment of hypertension, especially renin-associated hypertension.
    揭示了作为治疗剂有用的新型氨基酸衍生物。这些氨基酸衍生物及其药用盐在口服时具有人类肾素抑制作用,并可用于治疗高血压,特别是与肾素相关的高血压。
  • Novel amino acid derivatives
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:US04841067A1
    公开(公告)日:1989-06-20
    Novel amino acid derivatives useful as a therapeutic agent are disclosed. These amino acid derivatives and the pharmaceutically acceptable salts thereof have a human renin inhibitory effect when administered orally and are useful for treatment of hypertension, especially renin-associated hypertension.
    揭示了作为治疗剂有用的新型氨基酸衍生物。这些氨基酸衍生物及其药用盐在口服时具有人类肾素抑制作用,可用于治疗高血压,特别是与肾素相关的高血压。
查看更多